Bio Farma Requests Rp68bn Building Owned by Health Ministry as Non-cash Equity for Vaccine Development
Translator
Editor
3 July 2024 13:48 WIB
TEMPO.CO, Jakarta - PT Bio Farma (Persero), a state-owned manufacturer of human vaccines and antisera in Indonesia, is requesting for a non-cash state equity participation or inbreng in the form of state-owned goods or BMN worth Rp68 billion. The asset in question is a building owned by the Health Ministry constructed between 2006 and 2008 for the development of avian flu vaccines.
Bio Farma's president director, Shadiq Akasya, said the building was located on Bio Farma's land in Bandung. "The building and facilities are now on Bio Farma land. There are two locations, one in Pasteur and one in Cisarua," he said in a joint hearing with DPR Commission XI in Senayan on Tuesday, July 2.
Sadiq said the building was initially constructed in anticipation of the avian flu outbreak. The building is equipped with tools needed for production needs at that time. However, these assets have not been used to their full potential. Therefore, Sadiq said, the Ministry of Health wants to transfer these assets to Bio Farma.
"We still need them to complement the development of our two main productions now, which are rotavirus and rubella, the vaccines we are developing," said Shadiq.
He revealed that Bio Farma is currently still importing ingredients for the production of vaccines against rotavirus, one of the causes of diarrhea in children. "If we could manage it with BMN, it would be more optimal. Same with rubella. We still import it from India."
Bio Farma aims to have these assets ready for vaccine development by the end of 2025.
ANNISA FEBIOLA
Editor's Choice: 10 Best Universities in Indonesia for 2024
Click here to get the latest news updates from Tempo on Google News
